Leiden University Scholarly Publications

Search results

  • RSS Feed
(1 - 19 of 19)
Response to: 'Inconsistency between supplement and article?' by Babaoglu H
Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial
Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis
FOUR-YEAR IMAGING OUTCOMES IN AXIAL SPONDYLOARTHRITIS PATIENTS TREATED WITH CERTOLIZUMAB PEGOL, INCLUDING PATIENTS WITH ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis
Observed Incidence Rates of Uveitis over 96 Weeks of Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis
Structural Progression of the Spine Measured By X-Ray in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol over 96 Weeks, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
DISEASE ACTIVITY AND CLINICAL RESPONSE EARLY IN THE COURSE OF TREATMENT PREDICTS LONG-TERM OUTCOMES IN AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS PATIENTS TREATED WITH CERTOLIZUMAB PEGOL
Effect of Certolizumab Pegol over 96 Weeks of Treatment on Inflammation of Spine and Sacroiliac Joints Measured By Magnetic Resonance Imaging in Patients with Axial Spondyloarthritis
Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol
OBSERVED INCIDENCE RATES OF UVEITIS FOLLOWING CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS
Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
LONG-TERM SAFETY AND EFFICACY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 96-WEEK OUTCOMES OF THE RAPID-AXSPA TRIAL
Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
DISEASE ACTIVITY AND CLINICAL RESPONSE EARLY IN THE COURSE OF TREATMENT PREDICT LONG-TERM OUTCOMES IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH CERTOLIZUMAB PEGOL
DISEASE ACTIVITY AND CLINICAL RESPONSE EARLY IN THE COURSE OF TREATMENT PREDICT LONG-TERM OUTCOMES IN AXIAL SPONDYLOARTHRITIS PATIENTS TREATED WITH CERTOLIZUMAB PEGOL
LONG-TERM SAFETY AND EFFICACY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 96-WEEK OUTCOMES OF THE RAPID-AXSPA TRIAL
COMPARING HEALTH-RELATED QUALITY OF LIFE ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS: ANALYSES FROM CERTOLIZUMAB PEGOL CLINICAL TRIAL BASELINE DATA